Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.
暂无分享,去创建一个
Jeih-San Liow | Nicholas Seneca | Sami S Zoghbi | Victor W Pike | Robert B Innis | Andrew Taku | S. Zoghbi | J. Liow | R. Gladding | V. Pike | R. Innis | Jinsoo Hong | N. Seneca | Jinsoo Hong | Neva Lazarova | Robert L Gladding | E. Tuan | Ed Tuan | A. Taku | N. Lazarova
[1] Michael J. Welch,et al. Imaging Multidrug Resistance P-glycoprotein Transport Function Using MicroPET with Technetium-94m-Sestamibi , 2005, Molecular imaging.
[2] S. Binkley,et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. , 1999, The Journal of pharmacology and experimental therapeutics.
[3] Jeih-San Liow,et al. A single slice rebinning/2D exact positioning OSEM reconstruction for the NIH ATLAS small animal PET scanner , 2003 .
[4] Yiyun Huang,et al. 11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] I. Tamai,et al. Blood-brain barrier function of P-glycoprotein , 1997 .
[6] Richard E Carson,et al. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] J. Bart,et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.
[8] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[9] A. Fagan,et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.
[10] M. Melamed,et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[11] J. Humm,et al. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] A. Schinkel,et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.
[13] Joost Bart,et al. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. , 2004, Current pharmaceutical design.
[14] Division on Earth. Guide for the Care and Use of Laboratory Animals , 1996 .
[15] E. Masliah,et al. Altered P‐Glycoprotein Expression in AIDS Patients with HIV Encephalitis , 2004, Journal of neuropathology and experimental neurology.
[16] F. Yasuno,et al. Loperamide and its N-desmethyl radiometabolite are avid substrates for brain P-glycoprotein efflux , 2007 .
[17] Sami S Zoghbi,et al. Synthesis and evaluation in monkey of two sensitive 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. , 2008, Journal of medicinal chemistry.
[18] Yuichi Sugiyama,et al. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] Victor W. Pike,et al. Regional cerebral opioid receptor studies with [11C]diprenorphine in normal volunteers , 1988, Journal of Neuroscience Methods.
[20] Peter B. Reiner,et al. β‐Amyloid efflux mediated by p‐glycoprotein , 2001 .
[21] C. Wandel,et al. Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.
[22] Jeih-San Liow,et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] P. Janssen,et al. Synthetic antidiarrheal agents. 2,2-Diphenyl-4-(4'-aryl-4'-hydroxypiperidino)butyramides. , 1973, Journal of medicinal chemistry.
[24] R. Waterhouse,et al. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[25] G. D'aiuto,et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients , 1997, European Journal of Nuclear Medicine.
[26] M. Brock,et al. Imaging δ- and μ-Opioid Receptors by PET in Lung Carcinoma Patients , 2007 .
[27] A. Kalgutkar,et al. Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[28] P. Larsen,et al. Synthesis of [11C]iodomethane by iodination of [11C]methane , 1997 .
[29] D. Slate,et al. Methanodibenzosuberylpiperazines as potent multidrug resistance reversal agents , 1995 .
[30] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[31] Jeih-San Liow,et al. Effect of a P‐glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5‐HT1A receptor radioligand, [11C](R)‐(––)‐RWAY , 2007, Synapse.
[32] A. Megens,et al. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. , 1993, Digestive diseases and sciences.
[33] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[34] E. J. Simon,et al. Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuroleptic drugs. , 1977, European journal of pharmacology.
[35] C. D. Arnett,et al. A comparison of the brain uptake of N-(cyclopropyl[11C]methyl)norbuprenorphine ([11C]buprenorphine) and N-(cyclopropyl[11C]methyl)nordiprenorphine ([11C]diprenorphine) in baboon using PET. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[36] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[37] W Vaalburg,et al. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] Philip H. Elsinga,et al. Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain , 2005, Molecular Imaging and Biology.
[39] Jeih-San Liow,et al. 11C-Loperamide and Its N-Desmethyl Radiometabolite Are Avid Substrates for Brain Permeability-Glycoprotein Efflux , 2008, Journal of Nuclear Medicine.
[40] Christiane Kunert-Keil,et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. , 2002, Pharmacogenetics.
[41] A. Dantzig,et al. Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979 , 2003, International journal of cancer.
[42] S. Arakawa,et al. Metabolites of loperamide in rats. , 1979, Biomedical mass spectrometry.
[43] Jurgen Seidel,et al. Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: comparison to simulated LSO scanners without depth-of-interaction capability , 2001 .
[44] M. Brock,et al. Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] V. Pike. Positron-emitting radioligands for studies in vivo-probes for human psychopharmacology , 1993, Journal of psychopharmacology.